The Allstate Corporation · ALL · FY2024 Q3 · Calendar Q4 2024
Allstate pairs strong underwriting with retention and execution questions
The supplied analysis supports a constructive operating picture: stronger underwriting, new-business growth and product expansion are positives, but retention pressure and execution risks temper the outlook.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about ALL FY2024 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, the current analysis shows stronger reported underwriting and new-business momentum, while retention pressure from rate increases remains unresolved. Management also shifted capital-allocation emphasis toward organic growth and strategic acquisitions rather than buybacks.
Guidance delta
No formal guidance was provided in the supplied analysis; the main change was continued emphasis on growth investments and product rollouts.
Key takeaways
- Management highlighted 14.7% year-over-year revenue growth to $16.6 billion and adjusted EPS of $3.91.
- Auto and homeowners underwriting improved, while retention remained pressured by recent rate increases.
- New business grew 26% across channels as advertising investment increased and digital initiatives expanded.
- The company is prioritizing organic growth, ASC product rollouts and strategic acquisitions over share buybacks.
Management priorities
- Roll out Affordable Simple Connected auto and homeowners products.
- Expand Custom360 and invest in claims capabilities and customer experience.
- Pursue organic growth and selective acquisitions while completing the EVB sale.
Follow ALL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weight | Underweight | Upgrade | Oct 12, 2026 |
| Keefe, Bruyette & Woods | Underperform | Underperform | Maintain | Oct 12, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 7, 2026 |
| Barclays | Underweight | Underweight | Maintain | Oct 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 6, 2026 |
| Citigroup | Sell | Sell | Maintain | Oct 2, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 1, 2026 |
| Argus Research | Hold | Buy | Downgrade | Aug 28, 2026 |
| BMO Capital | Buy | Buy | Maintain | Aug 13, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 11, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 10, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 10, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Aug 7, 2026 |
| Roth MKM | Buy | Buy | Maintain | Aug 6, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Aug 6, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 9, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Jul 6, 2026 |
| HSBC | Hold | Buy | Downgrade | Jul 6, 2026 |
| TD Cowen | Hold | Buy | Downgrade | Jan 12, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Dec 18, 2025 |
| Roth Capital | Buy | Buy | Maintain | Nov 26, 2025 |
| Jefferies | Buy | Buy | Maintain | Aug 11, 2025 |
| B of A Securities | Buy | Buy | Maintain | Oct 18, 2024 |
| CFRA | Hold | Buy | Downgrade | Oct 21, 2022 |
| MKM Partners | Buy | Buy | Maintain | Oct 20, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Apr 28, 2022 |
| Wolfe Research | Perform | Peer Perform | Maintain | Aug 17, 2021 |
| Deutsche Bank | Hold | Hold | Maintain | May 13, 2021 |
| Buckingham Research | Neutral | Neutral | Maintain | Sep 12, 2019 |
| Buckingham | Neutral | Neutral | Maintain | Sep 12, 2019 |
| Compass Point | Buy | Buy | Maintain | Jan 15, 2019 |
| B. Riley Securities | Neutral | Neutral | Maintain | Aug 7, 2018 |
| B. Riley FBR | Neutral | Neutral | Maintain | Aug 7, 2018 |
| Argus | Buy | Buy | Maintain | May 9, 2018 |
| Keefe Bruyette & Woods | Market Perform | Underperform | Upgrade | Apr 2, 2018 |
| Bank of America | Buy | Buy | Maintain | Feb 8, 2018 |
| Macquarie | Neutral | Outperform | Downgrade | Apr 19, 2017 |
| Nomura | Neutral | Neutral | Maintain | Feb 4, 2016 |
| PiperJaffray | Overweight | Overweight | Maintain | Oct 15, 2015 |
| Sandler O'Neill | Buy | Hold | Upgrade | Sep 21, 2015 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Aug 4, 2015 |
| FBR Capital | Market Perform | Market Perform | Maintain | Oct 1, 2014 |
| Guggenheim | Buy | Buy | Maintain | Sep 18, 2013 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Sep 27, 2012 |
| Drexel Hamilton | Hold | Hold | Maintain | Aug 1, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $253.19. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Elyse Greenspan | $236 | $229.43 | -6.8% | Oct 12, 2026 |
| Mizuho Securities | Analyst unavailable | $295 | $224.27 | +16.5% | Oct 7, 2026 |
| Barclays | Alex Scott | $221 | $224.27 | -12.7% | Oct 7, 2026 |
| HSBC | Analyst unavailable | $266 | $224.27 | +5.1% | Oct 7, 2026 |
| Goldman Sachs | Analyst unavailable | $250 | $221.86 | -1.3% | Oct 1, 2026 |
| Mizuho Securities | Analyst unavailable | $300 | $252.21 | +18.5% | Sep 18, 2026 |
| Mizuho Securities | Analyst unavailable | $297 | $257.21 | +17.3% | Sep 16, 2026 |
| Argus Research | Kevin Heal | $238 | $257.62 | -6.0% | Aug 28, 2026 |
| Morgan Stanley | Analyst unavailable | $265 | $267.77 | +4.7% | Aug 11, 2026 |
| Raymond James | Analyst unavailable | $315 | $266.31 | +24.4% | Aug 11, 2026 |
| UBS | Analyst unavailable | $275 | $271.07 | +8.6% | Aug 10, 2026 |
| Goldman Sachs | Robert Cox | $280 | $275.11 | +10.6% | Aug 7, 2026 |
| Wells Fargo | Analyst unavailable | $250 | $275.11 | -1.3% | Aug 7, 2026 |
| Roth Capital | Analyst unavailable | $300 | $264.59 | +18.5% | Aug 6, 2026 |
| Barclays | Alex Scott | $226 | $264.59 | -10.7% | Aug 6, 2026 |
| Roth Capital | Analyst unavailable | $275 | $248.55 | +8.6% | Jul 17, 2026 |
| Atlantic Equities | Analyst unavailable | $319 | $240.55 | +26.0% | Jul 15, 2026 |
| UBS | Analyst unavailable | $261 | $250.35 | +3.1% | Jul 15, 2026 |
| Evercore ISI | David Motemaden | $240 | $250.59 | -5.2% | Jul 10, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $242 | $249.27 | -4.4% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $272 | $251.17 | +7.4% | Jul 9, 2026 |
| Barclays | Alex Scott | $213 | $248.37 | -15.9% | Jul 7, 2026 |
| Raymond James | Analyst unavailable | $300 | $248.04 | +18.5% | Jul 6, 2026 |
| Morgan Stanley | Bob Huang | $240 | $250.33 | -5.2% | Jul 6, 2026 |
| HSBC | Vikram Gandhi | $264 | $250.33 | +4.3% | Jul 6, 2026 |
| Piper Sandler | Analyst unavailable | $268 | $217.26 | +5.8% | May 1, 2026 |
| Raymond James | Gregory Peters | $260 | $213.61 | +2.7% | Mar 3, 2026 |
| Mizuho Securities | Analyst unavailable | $281 | $207.55 | +11.0% | Feb 9, 2026 |
| Goldman Sachs | Analyst unavailable | $238 | $207.55 | -6.0% | Feb 7, 2026 |
| Wells Fargo | Elyse Greenspan | $228 | $212.13 | -9.9% | Feb 6, 2026 |
| Mizuho Securities | Analyst unavailable | $255 | $197.65 | +0.7% | Jan 14, 2026 |
| Wells Fargo | Analyst unavailable | $223 | $208.66 | -11.9% | Jan 13, 2026 |
| Goldman Sachs | Analyst unavailable | $227 | $207.27 | -10.3% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $225 | $208.97 | -11.1% | Jan 7, 2026 |
| Morgan Stanley | Bob Huang | $215 | $211.69 | -15.1% | Dec 16, 2025 |
| Mizuho Securities | Yaron Kinar | $254 | $211.69 | +0.3% | Dec 15, 2025 |
| Roth Capital | Harry Fong | $240 | $212.65 | -5.2% | Nov 26, 2025 |
| UBS | Analyst unavailable | $250 | $213.06 | -1.3% | Oct 8, 2025 |
| Evercore ISI | David Motemaden | $233 | $214.65 | -8.0% | Oct 1, 2025 |
| Roth Capital | Analyst unavailable | $230 | $209.82 | -9.2% | Sep 26, 2025 |
| Wells Fargo | Analyst unavailable | $202 | $205.55 | -20.2% | Aug 5, 2025 |
| Barclays | Alex Scott | $198 | $192.28 | -21.8% | Jul 31, 2025 |
| Wells Fargo | Elyse Greenspan | $197 | $200.17 | -22.2% | May 6, 2025 |
| Raymond James | Gregory Peters | $250 | $200.25 | -1.3% | May 5, 2025 |
| Wells Fargo | Elyse Greenspan | $187 | $186.04 | -26.1% | Jan 14, 2025 |
| BMO Capital | Michael Zaremski | $214 | $195.51 | -15.5% | Oct 18, 2024 |
| Bank of America Securities | Joshua Shanker | $233 | $195.51 | -8.0% | Oct 18, 2024 |
| Bank of America Securities | Joshua Shanker | $216 | $184.91 | -14.7% | Oct 10, 2024 |
| Raymond James | Gregory Peters | $220 | $187.84 | -13.1% | Oct 4, 2024 |
| Wells Fargo | Elyse Greenspan | $175 | $178.11 | -30.9% | Aug 16, 2024 |
| Piper Sandler | Paul Newsome | $196 | $178.11 | -22.6% | Aug 16, 2024 |
| CFRA | Catherine Seifert | $200 | $180.95 | -21.0% | Aug 14, 2024 |
| Wells Fargo | Elyse Greenspan | $177 | $171.03 | -30.1% | Aug 12, 2024 |
| Jefferies | Yaron Kinar | $217 | $169.02 | -14.3% | Aug 5, 2024 |
| BMO Capital | Michael Zaremski | $205 | $176.82 | -19.0% | Aug 5, 2024 |
| BMO Capital | Michael Zaremski | $191 | $176.69 | -24.6% | Jul 18, 2024 |
| Piper Sandler | Paul Newsome | $188 | $173.01 | -25.7% | Apr 1, 2024 |
| HSBC | Vikram Gandhi | $190 | $169.84 | -25.0% | Mar 28, 2024 |
| Wells Fargo | Analyst unavailable | $104 | $131.68 | -58.9% | Feb 3, 2023 |
| Evercore ISI | Analyst unavailable | $138 | $131.53 | -45.5% | Feb 2, 2023 |
| Piper Sandler | Analyst unavailable | $153 | $140.01 | -39.6% | Jan 10, 2023 |
| Goldman Sachs | Analyst unavailable | $166 | $140.36 | -34.4% | Jan 9, 2023 |
| Morgan Stanley | Analyst unavailable | $137 | $134.26 | -45.9% | Nov 22, 2022 |
| Credit Suisse | Andrew Kligerman | $188 | $121.39 | -25.7% | Sep 2, 2022 |
| Morgan Stanley | Analyst unavailable | $140 | $131.18 | -44.7% | Aug 19, 2022 |
| Piper Sandler | Analyst unavailable | $147 | $141.13 | -41.9% | Apr 22, 2022 |
| Raymond James | Gregory Peters | $165 | $141.8 | -34.8% | Mar 27, 2022 |
| Raymond James | Gregory Peters | $145 | $125.88 | -42.7% | Mar 14, 2022 |
| Goldman Sachs | Alex Scott | $142 | $125.68 | -43.9% | Mar 3, 2022 |
| Jefferies | Yaron Kinar | $122 | $121.54 | -51.8% | Jan 6, 2022 |
| Barclays | Tracy Benguigui | $119 | $121.54 | -53.0% | Jan 6, 2022 |
| Deutsche Bank | Phil Stefano | $131 | $134 | -48.3% | May 13, 2021 |
| Argus Research | Kevin Heal | $155 | $131.05 | -38.8% | May 10, 2021 |
Track every rating change on ALL the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Allstate Corporation, along with its affiliated entities, provides a comprehensive suite of property, casualty, and other insurance offerings throughout the United States and Canada. The company's operations are structured across four primary business segments: Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability. The Allstate Protection segment delivers a wide array of personal and commercial insurance solutions. This includes standard private passenger auto and homeowners policies, as well as specialized vehicle coverage for motorcycles, trailers, motor homes, and off-road vehicles. Additional personal lines encompass renter, condominium, landlord, boat, umbrella, manufactured home, and stand-alone scheduled personal property policies. Commercial lines products are also available, marketed under the Allstate and Encompass brand names. The Protection Services division focuses on consumer protection and related financial services.…
Historical context
All ALL earningsFinancial Services peers this season
Latest reports in the same sectorLatest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the ALL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-24T13:50:40.346841+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T13:50:40.343921+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.